BioSpace News Archive

Akumin Inc. announced the departure of its President and Co-Chief Executive Officer, Rhonda Longmore-Grund, effective , following the decision by its board of directors to not continue with the co-CEO arrangement.

Arcturus Therapeutics Holdings Inc. announced that the Compensation Committee of the Company’s Board of Directors and the Company’s Board of Directors approved inducement grants of stock options to purchase an aggregate of 20,000 shares of Arcturus’ common stock to two newly-hired employee.

The Melanoma Research Alliance (MRA) released the following statements from MRA’s Chief Science Officer Marc Hurlbert, PhD and President & CEO Michael Kaplan on the Food & Drug Administration approval of relatlimab plus nivolumab.

NRx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, announced that the company’s Board of Directors appointed Ira Strassberg as Chief Financial Officer and Treasurer effective March 15, 2022.

Orphazyme A/S announces that following the Company’s filing of a petition for an in-court restructuring (in Danish rekonstruktion) of Orphazyme on March 10, 2022, the Danish Maritime and Commercial High Court (the “Court”) has commenced the restructuring proceedings of the Company on March 11, 2022 at 7:00 am (CET).

On March 18, 2022, Lynk Pharmaceuticals Co., Ltd. (Lynk Pharmaceuticals) and Simcere (2096.HK) announced a strategic partnership to develop and commercialize a highly selective JAK1 inhibitor LNK01001 in China.

I-Mab (the “Company”) (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that the Company will report financial results for the full year ended December 31, 2021 before the market opens on Tuesday, March 29, 2022.

Melzi Surgical (“Melzi” or the “Company”), a surgical device company dedicated to creating innovative technologies that improve patient outcomes while reducing hospital expenses, announced today that Reid Rutherford, Chief Executive Officer, will present at the Life Science Intelligence (LSI) USA ’22 Emerging Medtech Summit.

MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, reported financial results for the fourth quarter and full year 2021.

Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical stage biopharmaceutical company advancing oral therapies to aid patients suffering with acute and chronic gastrointestinal (GI) complications, today provides a business update and reports its financial results for the year ended December 31, 2021.